跳至主要内容
临床试验/KCT0006322
KCT0006322尚未招募未知

The prospective non-randomized case-control study to elucidate optimal target population of immunotherapy from real-world lung cancer patients

Samsung Medical Center0 个研究点目标入组 800 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
19?(Year) 至 o Limit(—)
性别
All

入选标准

  • 1.Immunotherapy group
  • ? Male and female patients must be at least 19 years of age.
  • ? Patients with histologically confirmed NSCLC
  • ? Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
  • ? Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
  • ? Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties)

排除标准

  • 1. Immunochemotherapy group
  • ? Patients receiving immunotherapy without reimbursement
  • ? Patients who do not provide consent to the study
  • 2. Cytotoxic chemotherapy group
  • ? Patients receiving cytotoxic chemotherapy without reimbursement
  • ? Patients who do not provide consent to the study

研究者

相似试验